false
--12-31
0001692415
0001692415
2026-11-19
2026-11-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): November 19, 2026
CO-DIAGNOSTICS,
INC.
(Exact
name of registrant as specified in its charter)
Commission
File No. 001-38148
| Utah |
|
46-2609363 |
| (State
or other jurisdiction |
|
(IRS
Employer |
| of
incorporation) |
|
Identification
Number) |
2401
S. Foothill Drive, Suite D
Salt
Lake City, Utah 84108
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (801) 438-1036
Former
name or former address, if changed since last report: Not Applicable
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, par value $0.001 per share |
|
CODX |
|
The
Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
3.03 - Material Modification to Rights of Security Holders.
As
previously disclosed, on November 13, 2026, at a special meeting of the stockholders of Co-Diagnostics, Inc. (the “Company”),
the Company’s stockholders approved an amendment to the Company’s Articles of Incorporation, as amended, to effect one or
more reverse stock splits of the Company’s issued and outstanding shares of common stock, on one or more occasions, at a ratio
of not less than 1-for-2, with the cumulative effect of all such reverse stock splits not to exceed 1-for-750, such final ratio or ratios
and the timing and number of any reverse stock splits to be determined by the Company’s board of directors (the “Board”)
at any time within twelve months following the special meeting, without further approval or authorization of the stockholders.
On
November 13, 2026, the Company’s Board approved a reverse stock split ratio of 1-for-25. The Company filed Articles of Amendment
to the Company’s Articles of Incorporation, as amended (the “Amendment”) with the Utah Division of Corporations and
Commercial Code on November 19, 2026, which will be effective at 12:01 a.m. Mountain Time on Tuesday, November 24, 2026. The Company’s
shares will begin trading on a split-adjusted basis on The Nasdaq Capital Market commencing upon market open on November 24, 2026. A
copy of the Amendment is attached hereto as Exhibit 3.1 and is incorporated herein by reference. This discussion is qualified in its
entirety by reference to the full text of the Amendment.
As
a result of the reverse stock split, every 25 shares of the Company’s issued and outstanding common stock will be automatically
combined and converted into one (1) issued and outstanding share of common stock, par value $0.001 per share. The Company will not issue
any fractional shares in connection with the reverse stock split. Instead, each stockholder who would otherwise be entitled to receive
a fractional share will receive one whole share of common stock in lieu of such fractional share. The reverse stock split will not modify
the rights or preferences of the common stock. The reverse stock split will also not change the number of shares of capital stock authorized
for issuance under our Articles of Incorporation.
Immediately
after the reverse stock split becomes effective, there will be approximately 521,779 shares of common stock issued and outstanding. The
common shares will trade under a new CUSIP number, 189763 303, effective November 24, 2026, and continue to trade under the symbol “CODX.”
All stock options and warrants of the Company outstanding immediately prior to the reverse stock split will be proportionally adjusted
in accordance with their respective terms.
The
Company has appointed its transfer agent, VStock Transfer, LLC, to act as exchange agent for the reverse stock split. Stockholders owning
shares via a bank, broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split and will
not be required to take further action in connection with the reverse stock split, subject to brokers’ particular processes.
Item
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
The
information set forth in Item 3.03 of this Current Report on Form 8-K is incorporated herein by reference.
Item
7.01. Regulation FD. Disclosure.
On
November 19, 2026, the Company issued a press release announcing the reverse stock split. The full text of the press release is furnished
as Exhibit 99.1 to this Form 8-K.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
| Exhibit
Number |
|
Description |
| 3.1 |
|
Articles of Amendment to the Articles of Incorporation of Co-Diagnostics, Inc. |
| 99.1 |
|
Press release dated November 19, 2026. |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
|
|
CO-DIAGNOSTICS,
INC. |
| |
|
|
|
|
| Date: |
November
19, 2026 |
|
By: |
/s/
Daniel Bohrer |
| |
|
|
|
Daniel
Bohrer |
| |
|
|
|
Executive
Vice President Finance & Accounting (Principal Financial and Accounting Officer) |
Exhibit
99.1
Co-Diagnostics
Announces Reverse Stock Split
SALT
LAKE CITY, Nov. 19, 2026 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (“Co-Diagnostics” or “the
Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,
today announced that it has filed Articles of Amendment to its Articles of Incorporation (the “Amendment”) to effect a reverse
stock split of its issued and outstanding common stock at a ratio of 1-for-25 shares (the “Reverse Stock Split”). The Reverse
Stock Split will become effective at 12:01 a.m. ET on Tuesday, November 24, 2026. The Company’s common stock will continue to trade
on The Nasdaq Capital Market under the symbol “CODX” and will begin trading on a split-adjusted basis when the market opens
on Tuesday, November 24, 2026. The Reverse Stock Split is intended to enable the Company to maintain compliance with the $1.00 minimum
bid price requirement for continued listing on The Nasdaq Capital Market, and to maintain sufficient authorized shares available for
issuance to allow the Company to conduct equity financings as needed. The new CUSIP number for the Company’s common stock following
the Reverse Stock Split will be 189763 303.
At
the Special Meeting of Stockholders held on November 13, 2026 (the “Special Meeting”), the Company’s stockholders approved
an amendment to the Company’s Articles of Incorporation, as amended, to effect one or more reverse stock splits of the Company’s
issued and outstanding shares of common stock, on one or more occasions, at a ratio of not less than 1-for-2, with the cumulative effect
of all such reverse stock splits not to exceed 1-for-750, such final ratio or ratios and the timing and number of any reverse stock splits
to be determined by the Company’s board of directors at any time within twelve months following the Special Meeting, without further
approval or authorization of the stockholders. Additional information regarding the Reverse Stock Split approved by stockholders can
be found in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”)
on October 26, 2026.
The
Amendment provides that at the effective time of the Reverse Stock Split, each 25 shares of the Company’s issued and outstanding
common stock will be automatically combined into one (1) validly issued, fully paid and non-assessable share of common stock, without
effecting a change to the par value per share. The Reverse Stock Split will impact all shares of the Company’s common stock outstanding
immediately prior to the effective time of the Reverse Stock Split, as well as the number of shares of common stock available for issuance
under the Company’s equity incentive plans. In addition, the Reverse Stock Split will effect a reduction in the number of shares
of common stock issuable upon the exercise of stock options and warrants outstanding immediately prior to the effectiveness of the Reverse
Stock Split with a corresponding increase in the applicable exercise price per share, in each case in accordance with the terms thereof.
The Reverse Stock Split will not change the number of shares of capital stock authorized for issuance under our Articles of Incorporation.
Based on the 13,044,465 shares of common stock currently outstanding, we expect approximately 521,779 shares of common stock to be issued
and outstanding following the Reverse Stock Split.
No
fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive
fractional shares as a result of the Reverse Stock Split will have those shares rounded up to the next whole share. Stockholders with
shares in brokerage accounts should direct any questions concerning the reverse stock split to their broker; all other stockholders may
direct questions to the Company’s transfer agent, VStock Transfer, LLC.
About
Co-Diagnostics, Inc.:
Co-Diagnostics,
Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies.
The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules
(DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform
(subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious
disease.
Forward-Looking
Statements
This
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”)
that are subject to a number of risks and uncertainties. Readers are cautioned not to place undue reliance on the forward-looking statements,
which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and
beliefs. There can be no assurance that implementing a reverse stock split will result in the Company maintaining compliance with Nasdaq
listing requirements or that the Company will be able to conduct equity financings in the future. A discussion of additional risks and
uncertainties can be found in the Company’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March
31, 2026, and in the Company’s other filings with the SEC, including Quarterly Reports on Form 10-Q. Co-Diagnostics undertakes
no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date
of this press release.
For
further information: Investor Contact: Valter Pinto, Managing Director, KCSA Strategic Communications, +1 212.896.1254, CODX@KCSA.com;
Media Contact: Jennifer Webb, ColtrinMethod PR, jcoltrin@coltrinmethodpr.com.